Clinical Trial

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-07-17; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT03222674
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Acute Myeloid Leukemia
Enrollment 10 participants
Start Date 2025-07-15
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23